Loading organizations...

Catalyst OrthoScience is a technology company.
Catalyst OrthoScience has raised $66.0M across 6 funding rounds.
Catalyst OrthoScience has raised $66.0M in total across 6 funding rounds.
Catalyst OrthoScience is dedicated to advancing shoulder arthroplasty by creating innovative, less invasive surgical solutions that improve patient outcomes and enhance operational efficiency for surgeons.
Catalyst OrthoScience has raised $66.0M in total across 6 funding rounds.
Catalyst OrthoScience's investors include Mutual Capital Partners, Bill Wickline, Motivate Ventures, Vitalize Venture Group.
Catalyst OrthoScience is a medical technology company specializing in innovative shoulder arthroplasty solutions designed to make shoulder replacement surgery less invasive and more efficient for both surgeons and patients. Their flagship products include the Archer™ CSR Total Shoulder System and the Archer™ R1 Reverse Shoulder System, along with the Archer™ 3D Targeting imaging software that supports preoperative planning. These products serve orthopedic surgeons and patients requiring shoulder replacement, addressing challenges such as preserving bone and soft tissue, improving surgical precision, and enhancing recovery outcomes. The company has demonstrated strong growth momentum, expanding its product portfolio and achieving FDA clearances, with its technologies now used across more than 40 states in the U.S.[1][2][3][5][7]
Founded in 2014 by Dr. Steven Goldberg, a fellowship-trained orthopedic surgeon and shoulder specialist, Catalyst OrthoScience emerged from his vision to develop a next-generation shoulder replacement system that is more precise and less invasive. Dr. Goldberg began developing the revolutionary implant design in 2011, leveraging 3D printing and securing patents before launching the Catalyst CSR Total Shoulder System. Early milestones included FDA approval in 2016 and angel investment that fueled growth from a small home-based operation to a company with over 50 employees and a broad patent portfolio. The company’s evolution has been marked by continuous innovation and expanding clinical adoption.[1][4][5][7]
Catalyst OrthoScience rides the growing trend of minimally invasive and precision orthopedic surgery, particularly in the expanding shoulder arthroplasty market—the fastest-growing segment in orthopedics. Advances in imaging, implant design, and surgical planning software align with broader healthcare shifts toward value-based care, improved patient outcomes, and cost efficiency. Catalyst’s innovations reduce complications and improve functional recovery, influencing standards in shoulder replacement surgery and encouraging adoption of technology-driven surgical solutions across the orthopedic ecosystem.[1][3][6][7]
Looking ahead, Catalyst is positioned to continue expanding its market share with new product releases like the Catalyst Fracture Shoulder System, which addresses complex proximal humeral fractures with patented technology. Trends shaping their journey include increasing demand for outpatient and less invasive orthopedic procedures, advances in 3D imaging and surgical planning, and growing emphasis on personalized implants. Catalyst’s influence is likely to grow as it further integrates digital tools and clinical data to optimize surgical outcomes, potentially setting new benchmarks in shoulder arthroplasty and orthopedic innovation.[3][7]
In sum, Catalyst OrthoScience exemplifies how surgeon-led innovation combined with advanced technology can transform a specialized surgical field, making shoulder replacement safer, more efficient, and more effective for patients and providers alike.
Catalyst OrthoScience has raised $66.0M across 6 funding rounds. Most recently, it raised $15.0M Other Equity in October 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 22, 2025 | $15.0M Other Equity | Mutual Capital Partners | |
| Sep 10, 2024 | $20.0M Other Equity | Bill Wickline, Mutual Capital Partners | |
| Oct 6, 2021 | $12.3M Series D | Mutual Capital Partners | |
| May 14, 2019 | $12.7M Series C | ||
| Nov 1, 2017 | $4.0M Series C | Motivate Ventures, Vitalize Venture Group | |
| Sep 1, 2016 | $2.0M Venture Round | Motivate Ventures, Vitalize Venture Group |